PRCT vs. STVN, IRTC, BLCO, GKOS, TMDX, NVST, SLNO, LIVN, WRBY, and EYE
Should you be buying PROCEPT BioRobotics stock or one of its competitors? The main competitors of PROCEPT BioRobotics include Stevanato Group (STVN), iRhythm Technologies (IRTC), Bausch + Lomb (BLCO), Glaukos (GKOS), TransMedics Group (TMDX), Envista (NVST), Soleno Therapeutics (SLNO), LivaNova (LIVN), Warby Parker (WRBY), and National Vision (EYE). These companies are all part of the "medical equipment" industry.
PROCEPT BioRobotics vs. Its Competitors
Stevanato Group (NYSE:STVN) and PROCEPT BioRobotics (NASDAQ:PRCT) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.
Stevanato Group has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, PROCEPT BioRobotics has a beta of 0.99, suggesting that its stock price is 1% less volatile than the S&P 500.
Stevanato Group has a net margin of 11.73% compared to PROCEPT BioRobotics' net margin of -30.60%. Stevanato Group's return on equity of 10.34% beat PROCEPT BioRobotics' return on equity.
89.5% of PROCEPT BioRobotics shares are owned by institutional investors. 17.4% of PROCEPT BioRobotics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, PROCEPT BioRobotics had 1 more articles in the media than Stevanato Group. MarketBeat recorded 6 mentions for PROCEPT BioRobotics and 5 mentions for Stevanato Group. PROCEPT BioRobotics' average media sentiment score of 0.85 beat Stevanato Group's score of 0.75 indicating that PROCEPT BioRobotics is being referred to more favorably in the news media.
PROCEPT BioRobotics has a consensus target price of $70.00, suggesting a potential upside of 112.12%. Given PROCEPT BioRobotics' higher probable upside, analysts clearly believe PROCEPT BioRobotics is more favorable than Stevanato Group.
Stevanato Group has higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.
Summary
Stevanato Group beats PROCEPT BioRobotics on 9 of the 17 factors compared between the two stocks.
Get PROCEPT BioRobotics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRCT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PRCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PROCEPT BioRobotics Competitors List
Related Companies and Tools
This page (NASDAQ:PRCT) was last updated on 10/13/2025 by MarketBeat.com Staff
